Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Virtus

Virtus KAR Health Sciences Fund Institutional Class (HLHIX)

Ticker HLHIX · · Holdings as of Jun 30, 2026

Expense ratio
1.05%$105/yr per $10k
5-yr return
+3.8%annualized
1-yr return
+7.6%as of Dec 2025
Net assets
$91.7Mall share classes
Holdings
24

Bottom line

Is HLHIX a good fund? The bottom line

HLHIX is the Institutional Class share class of Virtus KAR Health Sciences Fund, a managed health care sector mutual fund from Virtus.

Annual fees run 1.05% — about $105 a year on every $10,000 invested, more expensive than 59% of health care sector funds we track.

It returned +7.6% over one year, +3.8% a year over five years, +7.1% a year over ten (as of Dec 31, 2025, per its prospectus).

With $91.7 million in net assets and 24 holdings, its largest position is Eli Lilly & Company (14.8%) and the top 10 make up 57.6% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Concentrated: top 10 holdings are 57.6% of assets

Updated Nov 19, 2026

What HLHIX invests in

The fund seeks long-term capital appreciation .

The fund pursues long-term capital appreciation in health sciences-related companies. The fund invests in a select group of health science-related companies believed by the funds subadviser to possess sustainable competitive advantages at prices the subadviser deems attractive. Under normal circumstances, the fund invests at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. As of the date of this prospectus, the fund considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities. Although the fund may invest in companies of any market capitalization, the fund does not currently intend to invest more than 15% of its assets in…

From the fund's prospectus (filed Oct 22, 2026).

HLHIX performance

Fund calendar-year total returns, 2020–2025 2020: +14.1%; 2021: +25.7%; 2022: −11.6%; 2023: +2.8%; 2024: −2.0%; 2025: +7.6% +14.1% 2020 +25.7% 2021 −11.6% 2022 +2.8% 2023 −2.0% 2024 +7.6% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
HLHIX+7.6%+3.8%+7.1%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full HLHIX performance history →

What HLHIX costs

On a $10,000 investment, HLHIX's 1.05% expense ratio costs about $105 a year. The prospectus estimates $1,367 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full HLHIX fee table →

HLHIX top 10 holdings

#Holding% of fund
1Eli Lilly & Company LLY14.84%
2West Pharmaceutical Services Inc WST5.92%
3Abbvie Inc ABBV5.52%
4Vertex Pharmaceuticals Inc VRTX5.32%
5Merck & Company Inc MRK5.06%
6Unitedhealth Group Inc UNH4.65%
7Mckesson Corp MCK4.57%
8Mettler-toledo International Inc MTD3.99%
9Intuitive Surgical Inc ISRG3.89%
10Amgen Inc AMGN3.85%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 57.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to HLHIX

More funds like HLHIX →

HLHIX FAQ

What is the expense ratio of HLHIX?
HLHIX's expense ratio is 1.05%, which works out to about $105 a year for every $10,000 invested. The prospectus estimates total costs of $1,367 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is HLHIX a good investment?
It depends on your goals, but the data points to: no front-end sales load; concentrated: top 10 holdings are 57.6% of assets. This is general information, not personalized advice.
What does HLHIX hold?
HLHIX's largest holdings are Eli Lilly & Company (14.8%), West Pharmaceutical Services Inc (5.9%), Abbvie Inc (5.5%), Vertex Pharmaceuticals Inc (5.3%), Merck & Company Inc (5.1%). It holds 24 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is HLHIX's 5-year return?
HLHIX returned +3.8% a year over the five years ending Dec 31, 2025, and +7.1% a year over ten years. Past performance does not guarantee future results.
Does HLHIX have a sales load?
No. HLHIX has no front-end sales charge.
Who manages HLHIX?
HLHIX is offered by Virtus through Virtus Investment Trust.